vs
Side-by-side financial comparison of MEDICAL PROPERTIES TRUST INC (MPW) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
MEDICAL PROPERTIES TRUST INC is the larger business by last-quarter revenue ($270.3M vs $177.4M, roughly 1.5× Pacira BioSciences, Inc.). MEDICAL PROPERTIES TRUST INC runs the higher net margin — 6.5% vs 1.6%, a 4.9% gap on every dollar of revenue. On growth, MEDICAL PROPERTIES TRUST INC posted the faster year-over-year revenue change (16.6% vs 5.0%). Over the past eight quarters, MEDICAL PROPERTIES TRUST INC's revenue compounded faster (-0.2% CAGR vs -0.2%).
Medical Properties Trust, Inc. (MPT) is an international real estate investment trust (REIT) based in Birmingham, Alabama that purchases and invests in healthcare facilities and for-profit healthcare holding companies, primarily in the United States and Europe. Their property acquisitions often come in the form of sale-leaseback agreements, in which the original property owner sells the property to MPT and becomes their tenant. MPT's tenants are generally subject to long-term triple net lease...
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
MPW vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $270.3M | $177.4M |
| Net Profit | $17.6M | $2.9M |
| Gross Margin | 95.8% | — |
| Operating Margin | 9.7% | 3.9% |
| Net Margin | 6.5% | 1.6% |
| Revenue YoY | 16.6% | 5.0% |
| Net Profit YoY | 104.3% | — |
| EPS (diluted) | $0.03 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $270.3M | $196.9M | ||
| Q3 25 | $237.5M | $179.5M | ||
| Q2 25 | $240.4M | $181.1M | ||
| Q1 25 | $223.8M | $168.9M | ||
| Q4 24 | $231.8M | $187.3M | ||
| Q3 24 | $225.8M | $168.6M | ||
| Q2 24 | $266.6M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $17.6M | — | ||
| Q3 25 | $-77.7M | $5.4M | ||
| Q2 25 | $-98.4M | $-4.8M | ||
| Q1 25 | $-118.3M | $4.8M | ||
| Q4 24 | $-412.3M | — | ||
| Q3 24 | $-801.2M | $-143.5M | ||
| Q2 24 | $-320.6M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 95.8% | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | 91.8% | 77.4% | ||
| Q1 25 | 63.6% | 79.7% | ||
| Q4 24 | 90.9% | 78.7% | ||
| Q3 24 | 96.5% | 76.9% | ||
| Q2 24 | 98.4% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 9.7% | 1.2% | ||
| Q3 25 | -28.0% | 3.5% | ||
| Q2 25 | -36.7% | 4.7% | ||
| Q1 25 | -48.5% | 1.2% | ||
| Q4 24 | -173.7% | 13.2% | ||
| Q3 24 | -350.7% | -82.8% | ||
| Q2 24 | -114.5% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 6.5% | — | ||
| Q3 25 | -32.7% | 3.0% | ||
| Q2 25 | -40.9% | -2.7% | ||
| Q1 25 | -52.8% | 2.8% | ||
| Q4 24 | -177.8% | — | ||
| Q3 24 | -354.8% | -85.1% | ||
| Q2 24 | -120.3% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.03 | $0.05 | ||
| Q3 25 | $-0.13 | $0.12 | ||
| Q2 25 | $-0.16 | $-0.11 | ||
| Q1 25 | $-0.20 | $0.10 | ||
| Q4 24 | $-0.68 | $0.38 | ||
| Q3 24 | $-1.34 | $-3.11 | ||
| Q2 24 | $-0.54 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $540.9M | $144.3M |
| Total DebtLower is stronger | $9.7B | — |
| Stockholders' EquityBook value | $4.6B | $653.9M |
| Total Assets | $15.0B | $1.2B |
| Debt / EquityLower = less leverage | 2.11× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $540.9M | $238.4M | ||
| Q3 25 | $396.6M | $246.3M | ||
| Q2 25 | $509.8M | $445.9M | ||
| Q1 25 | $673.5M | $493.6M | ||
| Q4 24 | $332.3M | $484.6M | ||
| Q3 24 | $275.6M | $453.8M | ||
| Q2 24 | $606.5M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $9.7B | $372.2M | ||
| Q3 25 | $9.6B | $376.7M | ||
| Q2 25 | $9.6B | $580.5M | ||
| Q1 25 | $9.5B | $583.4M | ||
| Q4 24 | $8.8B | $585.3M | ||
| Q3 24 | $9.2B | — | ||
| Q2 24 | $9.4B | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $4.6B | $693.1M | ||
| Q3 25 | $4.7B | $727.2M | ||
| Q2 25 | $4.8B | $757.8M | ||
| Q1 25 | $4.8B | $798.5M | ||
| Q4 24 | $4.8B | $778.3M | ||
| Q3 24 | $5.4B | $749.6M | ||
| Q2 24 | $6.2B | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $15.0B | $1.3B | ||
| Q3 25 | $14.9B | $1.3B | ||
| Q2 25 | $15.2B | $1.5B | ||
| Q1 25 | $14.9B | $1.6B | ||
| Q4 24 | $14.3B | $1.6B | ||
| Q3 24 | $15.2B | $1.5B | ||
| Q2 24 | $16.2B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 2.11× | 0.54× | ||
| Q3 25 | 2.06× | 0.52× | ||
| Q2 25 | 2.00× | 0.77× | ||
| Q1 25 | 1.99× | 0.73× | ||
| Q4 24 | 1.83× | 0.75× | ||
| Q3 24 | 1.69× | — | ||
| Q2 24 | 1.51× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $230.8M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 13.11× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $230.8M | $43.7M | ||
| Q3 25 | $18.6M | $60.8M | ||
| Q2 25 | $51.7M | $12.0M | ||
| Q1 25 | $384.0K | $35.5M | ||
| Q4 24 | $245.5M | $33.1M | ||
| Q3 24 | $59.2M | $53.9M | ||
| Q2 24 | $35.3M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $43.5M | ||
| Q3 25 | — | $57.0M | ||
| Q2 25 | — | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | — | $49.8M | ||
| Q2 24 | — | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 22.1% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | — | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 13.11× | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MPW
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
